idx320

IDX320 is a potent non-covalent macrocyclic small molecule inhibitor of the hepatitis C virus (HCV) NS3/4A protease. Developed by Idenix Pharmaceuticals, it was designed for oral administration and demonstrated nanomolar potency against multiple HCV genotypes (1a, 1b, 2a, 3a, and 4a), with high selectivity over human cellular proteases. IDX320 showed favorable pharmacokinetics in preclinical models and healthy volunteers—including good bioavailability and a long plasma half-life—supporting once-daily dosing. In clinical studies (Phase I/II), it produced dose-dependent reductions in HCV RNA in treatment-naive patients with chronic hepatitis C. The drug development was discontinued after Phase I/II trials[1][5][6][7][8].

Other names

UNII-LOV58XHF8IUNII-LOV-58XHF8IUNII-LOV 58XHF8ILOV58XHF8ILOV-58XHF8ILOV 58XHF8I